Christensen Michael, Hannan Raquibul
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Cancers (Basel). 2022 Sep 27;14(19):4693. doi: 10.3390/cancers14194693.
Advancements in radiation delivery technology have made it feasible to treat tumors with ablative radiation doses via stereotactic ablative radiation therapy (SAbR) at locations that were previously not possible. Renal cell cancer (RCC) was initially thought to be radioresistant, even considered toxic, in the era of conventional protracted course radiation. However, SAbR has been demonstrated to be safe and effective in providing local control to both primary and metastatic RCC by using ablative radiation doses. SAbR can be integrated with other local and systemic therapies to provide optimal management of RCC patients. We will discuss the rationale and available evidence for the integration and sequencing of SAbR with local and systemic therapies for RCC.
放射治疗技术的进步使得通过立体定向消融放疗（SAbR）以消融剂量治疗以前无法治疗部位的肿瘤成为可能。在传统的长疗程放疗时代，肾细胞癌（RCC）最初被认为具有放射抗性，甚至被认为是放疗毒性的。然而，已证明SAbR通过使用消融剂量对原发性和转移性RCC提供局部控制是安全有效的。SAbR可以与其他局部和全身治疗相结合，以提供对RCC患者的最佳管理。我们将讨论SAbR与RCC的局部和全身治疗相结合及序贯治疗的基本原理和现有证据。
